Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
3.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

5.9K
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
1.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Qing-Re-Hua-Shi Decoction ameliorates DSS-induced colitis by modulating multiple signaling pathways and remodeling the gut microbiota and metabolite profile.

Frontiers in cellular and infection microbiology·2025
Same author

Helicobacter Pylori-Enhanced hnRNPA2B1 Coordinates with PABPC1 to Promote Non-m<sup>6</sup>A Translation and Gastric Cancer Progression.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

CircUGGT2 downregulation by METTL14-dependent m<sup>6</sup>A modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186-3p/MAP3K9 axis.

Pharmacological research·2024
Same author

Detachable string magnetically controlled capsule endoscopy for the noninvasive diagnosis of esophageal diseases: A prospective, blind clinical study.

World journal of gastroenterology·2024
Same author

Corrigendum to: "Dihydroartemisinin inhibits the growth and invasion of gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling" [Pathol. Res. Pract. 216 (2020) 152795].

Pathology, research and practice·2023
Same author

m<sup>6</sup>A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.

Cellular signalling·2023

Related Experiment Video

Updated: Mar 17, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

LncRNAs and cancer.

Rui Zhang1, Li Qiong Xia1, Wen Wen Lu1

  • 1Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital, Shanghai 200233, P.R. China.

Oncology Letters
|July 23, 2016
PubMed
Summary

Long non-coding RNAs (lncRNAs) are crucial in cancer development. This review explores lncRNAs in various cancers, highlighting their diagnostic and therapeutic potential.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Long non-coding RNAs (lncRNAs) are RNA molecules longer than 200 nucleotides.
  • Emerging evidence implicates lncRNAs in the pathogenesis of various cancers.
  • Their precise roles and mechanisms in cancer progression are under active investigation.

Purpose of the Study:

  • To review the involvement of key lncRNAs in cancers of the digestive, respiratory, reproductive, urinary, and central nervous systems.
  • To elucidate the molecular and biochemical mechanisms of lncRNA function in cancer.
  • To offer insights into the potential of lncRNAs for cancer diagnosis and treatment.

Main Methods:

  • Literature review of extensively investigated lncRNAs in human cancers.
  • Analysis of lncRNA functions including gene expression regulation (cis- and trans-), epigenetic modulation, and post-transcriptional control.
Keywords:
HOTAIRMALAT1cancerlong non-coding RNA

Related Experiment Videos

Last Updated: Mar 17, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
  • Synthesis of current knowledge on lncRNA involvement across multiple organ systems.

    • Main Results:

    • lncRNAs play significant roles in the development and progression of diverse cancers.
    • Mechanisms of action involve complex regulatory networks at genomic and post-transcriptional levels.
    • Specific lncRNAs are implicated in cancers of the digestive, respiratory, reproductive, urinary, and central nervous systems.

    Conclusions:

    • lncRNAs represent a promising area for novel cancer diagnostics and therapeutics.
    • Further research is needed to fully understand the biological functions and mechanisms of most lncRNAs.
    • Targeting lncRNAs may offer new avenues for cancer treatment strategies.